Indian Immunologicals' chikungunya, JE vaccines set for human studies
This article was originally published in Scrip
Executive Summary
Indian Immunologicals (IIL) is developing a live attenuated chikungunya vaccine in collaboration with an institute in the US. The firm, which hopes to see a fast track regulatory approach in India for some if its products, is also upbeat about the prospects of its vaccines for Japanese encephalitis (JE) and cervical cancer.